CD4 and acute myeloid leukemia: In addition, Tregs from AML patients inhibited the proliferation of both normal CD4+CD25− T cells (proliferation of CD4+CD25− T cells decreased from 91.8 to 50.1%) and AML CD4+CD25− T cells (proliferation of CD4+CD25− T cells decreased from 86.2 to 42.1%) compared with that of Tregs in the controls (Fig. 4c).